Zydus Wellness Ltd
Zydus Wellness operates as an integrated consumer Company with business encompassing the entire value chain in the development, production, marketing and distribution of health and wellness products. The product portfolio of the Company includes brands like Sugar free, Everyuth and Nutralite.(Source : 202003 Annual Report Page No: 83)
- Market Cap ₹ 12,260 Cr.
- Current Price ₹ 1,925
- High / Low ₹ 2,484 / 1,440
- Stock P/E 39.0
- Book Value ₹ 863
- Dividend Yield 0.26 %
- ROCE 5.33 %
- ROE 5.32 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Tax rate seems low
- Company has a low return on equity of 6.08% over last 3 years.
- Dividend payout has been low at 10.8% of profits over last 3 years
- Debtor days have increased from 34.6 to 44.4 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: FMCG Industry: Food - Processing - Indian
Part of BSE 400 MidSmallCap Index Nifty Microcap 250 BSE Fast Moving Consumer Goods BSE 250 SmallCap Index BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
388 | 404 | 431 | 397 | 431 | 513 | 843 | 1,767 | 1,867 | 2,009 | 2,255 | 2,328 | 2,520 | |
291 | 319 | 331 | 305 | 331 | 387 | 658 | 1,446 | 1,522 | 1,664 | 1,918 | 2,020 | 2,170 | |
Operating Profit | 97 | 85 | 100 | 91 | 99 | 125 | 185 | 321 | 344 | 345 | 337 | 308 | 350 |
OPM % | 25% | 21% | 23% | 23% | 23% | 24% | 22% | 18% | 18% | 17% | 15% | 13% | 14% |
16 | 19 | 28 | 32 | 32 | 35 | 28 | -33 | -123 | 10 | -5 | -0 | 22 | |
Interest | 0 | 0 | 0 | 0 | 1 | 2 | 30 | 140 | 84 | 26 | 16 | 24 | 17 |
Depreciation | 4 | 0 | 8 | 7 | 7 | 9 | 13 | 26 | 25 | 24 | 25 | 24 | 22 |
Profit before tax | 108 | 104 | 120 | 117 | 124 | 150 | 171 | 121 | 112 | 306 | 291 | 260 | 333 |
Tax % | 8% | 5% | 7% | 10% | 10% | 9% | -0% | -17% | -6% | -1% | -7% | -3% | |
99 | 98 | 111 | 105 | 111 | 137 | 171 | 142 | 119 | 309 | 310 | 267 | 319 | |
EPS in Rs | 24.85 | 24.69 | 27.88 | 26.43 | 27.89 | 34.27 | 29.33 | 24.58 | 18.66 | 48.54 | 48.78 | 41.94 | 50.16 |
Dividend Payout % | 24% | 24% | 22% | 25% | 23% | 23% | 17% | 20% | 27% | 10% | 10% | 12% |
Compounded Sales Growth | |
---|---|
10 Years: | 19% |
5 Years: | 23% |
3 Years: | 8% |
TTM: | 11% |
Compounded Profit Growth | |
---|---|
10 Years: | 11% |
5 Years: | 11% |
3 Years: | 4% |
TTM: | 4% |
Stock Price CAGR | |
---|---|
10 Years: | 11% |
5 Years: | 6% |
3 Years: | -1% |
1 Year: | 24% |
Return on Equity | |
---|---|
10 Years: | 7% |
5 Years: | 6% |
3 Years: | 6% |
Last Year: | 5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 39 | 39 | 39 | 39 | 39 | 39 | 58 | 58 | 64 | 64 | 64 | 64 | 64 |
Reserves | 217 | 286 | 367 | 439 | 518 | 652 | 3,329 | 3,403 | 4,504 | 4,780 | 5,059 | 5,294 | 5,431 |
0 | 0 | 0 | 0 | 25 | 25 | 1,569 | 1,519 | 550 | 387 | 297 | 329 | 154 | |
93 | 99 | 102 | 89 | 100 | 112 | 503 | 610 | 548 | 461 | 413 | 462 | 359 | |
Total Liabilities | 349 | 425 | 508 | 568 | 682 | 829 | 5,459 | 5,590 | 5,666 | 5,692 | 5,833 | 6,148 | 6,008 |
94 | 95 | 84 | 82 | 103 | 104 | 4,567 | 4,674 | 4,667 | 4,710 | 4,732 | 4,708 | 4,703 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 4 | 4 | 12 | 13 | 10 | 17 |
Investments | 0 | 5 | 0 | 94 | 30 | 148 | 46 | 110 | 0 | 27 | 70 | 78 | 367 |
255 | 324 | 423 | 391 | 550 | 577 | 835 | 802 | 995 | 943 | 1,018 | 1,354 | 921 | |
Total Assets | 349 | 425 | 508 | 568 | 682 | 829 | 5,459 | 5,590 | 5,666 | 5,692 | 5,833 | 6,148 | 6,008 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
69 | 91 | 69 | 90 | 77 | 69 | 149 | 259 | 287 | 237 | 92 | 246 | |
13 | 13 | 29 | -28 | -72 | -59 | -4,092 | -17 | -10 | -59 | -85 | -19 | |
-23 | -27 | -27 | -58 | -6 | -2 | 4,052 | -260 | -216 | -234 | -138 | -26 | |
Net Cash Flow | 59 | 77 | 71 | 4 | -1 | 8 | 109 | -18 | 60 | -56 | -132 | 201 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 1 | 2 | 1 | 3 | 3 | 6 | 42 | 24 | 18 | 26 | 34 | 44 |
Inventory Days | 120 | 108 | 76 | 73 | 127 | 113 | 393 | 168 | 158 | 135 | 146 | 150 |
Days Payable | 136 | 191 | 146 | 191 | 264 | 254 | 662 | 289 | 189 | 136 | 100 | 116 |
Cash Conversion Cycle | -14 | -82 | -69 | -116 | -134 | -135 | -227 | -97 | -13 | 25 | 80 | 78 |
Working Capital Days | -32 | -48 | -37 | -38 | -36 | -8 | 4 | -3 | 12 | 31 | 65 | 71 |
ROCE % | 48% | 35% | 32% | 26% | 23% | 22% | 7% | 6% | 6% | 6% | 6% | 5% |
Documents
Announcements
-
Receipt Of Order Under VAT Act
2d - Zydus Wellness faces ₹116.14 million tax appeal.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
15 Nov - Transcript of Q2 FY2025 Earnings Conference Call.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
12 Nov - Newspaper publication for unaudited financial results for the quarter and half year ended on September 30, 2024
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
11 Nov - Audio recording of investor call on Q2 results.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
11 Nov - Schedule of Analyst / Institutional Investors' Conference
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
Concalls
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
May 2022TranscriptNotesPPT
-
Feb 2022Transcript PPT
-
Oct 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
May 2021TranscriptPPT
-
Jan 2021TranscriptPPT
-
Oct 2020TranscriptPPT
-
Sep 2020TranscriptNotesPPT
-
Jul 2020TranscriptPPT
-
May 2020TranscriptPPT
-
Jan 2020TranscriptPPT
-
Nov 2019TranscriptPPT
-
Jul 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Oct 2018TranscriptPPT
-
Jul 2018TranscriptPPT
-
May 2018TranscriptPPT
-
Jan 2018TranscriptPPT
-
Nov 2017TranscriptPPT
-
Feb 2017TranscriptNotesPPT
-
Nov 2016Transcript PPT
-
Jul 2016TranscriptPPT
-
Jun 2016TranscriptNotesPPT
Product Portfolio
The Company’s product portfolio includes brands like Glucon-D, Complan, Sugar-Free, Nycil, Everyuth, and Nutralite offering products such as Glucose Powder, Face wash, Scrub, Peel-Off, Face masks, Sugar Substitute, Blended Sugar, etc [1]